These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31480004)

  • 21. Novel insights into paclitaxel's role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment.
    Choi Y; Kim SA; Jung H; Kim E; Kim YK; Kim S; Kim J; Lee Y; Jo MK; Woo J; Cho Y; Lee D; Choi H; Jeong C; Nam GH; Kwon M; Kim IS
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39009452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
    Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
    Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
    Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells.
    He J; Wink S; de Bont H; Le Dévédec S; Zhang Y; van de Water B
    Biochem Pharmacol; 2019 Nov; 169():113640. PubMed ID: 31536726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer.
    Sato N; Wakabayashi M; Nakatsuji M; Kashiwagura H; Shimoji N; Sakamoto S; Ishida A; Lee J; Lim B; Ueno NT; Ishihara H; Inui T
    Biochem Biophys Res Commun; 2017 Aug; 489(4):484-489. PubMed ID: 28576487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
    Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
    Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
    Sami E; Paul BT; Koziol JA; ElShamy WM
    Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.
    Staquicini FI; Hajitou A; Driessen WH; Proneth B; Cardó-Vila M; Staquicini DI; Markosian C; Hoh M; Cortez M; Hooda-Nehra A; Jaloudi M; Silva IT; Buttura J; Nunes DN; Dias-Neto E; Eckhardt B; Ruiz-Ramírez J; Dogra P; Wang Z; Cristini V; Trepel M; Anderson R; Sidman RL; Gelovani JG; Cristofanilli M; Hortobagyi GN; Bhujwalla ZM; Burley SK; Arap W; Pasqualini R
    Elife; 2021 Jun; 10():. PubMed ID: 34060472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
    Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
    Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer.
    Wang X; Yu J; Liu X; Luo D; Li Y; Song L; Jiang X; Yin X; Wang Y; Chai L; Luo T; Jing J; Shi H
    Cell Rep Med; 2022 Sep; 3(9):100741. PubMed ID: 36099919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk.
    Wang L; Zhang L; Zhao L; Shao S; Ning Q; Jing X; Zhang Y; Zhao F; Liu X; Gu S; Zhao X; Luo M
    Int J Biol Sci; 2024; 20(2):446-463. PubMed ID: 38169627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metalloprotease-dependent activation of EGFR modulates CD44
    Wise R; Zolkiewska A
    Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression.
    Hong L; Tanaka M; Yasui M; Hara-Chikuma M
    Sci Rep; 2024 Sep; 14(1):22541. PubMed ID: 39341960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Salvianolic Acid A on Tumor-Associated Macrophage Polarization and Its Mechanisms in the Tumor Microenvironment of Triple-Negative Breast Cancer.
    Tang C; Jiang ST; Li CX; Jia XF; Yang WL
    Molecules; 2024 Mar; 29(7):. PubMed ID: 38611749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.